Cannabis Employment Protections: State Laws, Court Rulings & Worker Rights

Executive Summary

Cannabis employment protections remain a patchwork of state laws, court rulings, and regulatory guidance that determine whether workers can be fired, denied jobs, or face other adverse employment actions for legal marijuana use outside of work. As of May 2026, 23 states and the District of Columbia have enacted explicit statutory protections preventing employers from discriminating against employees or applicants based on off-duty cannabis consumption or positive drug tests, yet enforcement remains inconsistent and exceptions abound. The issue gained renewed attention in May 2026 when two Jersey City police officers won an appellate court ruling affirming they were wrongfully terminated for off-duty marijuana use, yet the city refused to reinstate them despite the court's decision. This case exemplifies the ongoing tension between state legalization frameworks, employer drug policies, federal prohibition under 21 U.S.C. § 812, and safety-sensitive position exemptions that create legal gray zones for millions of cannabis-consuming workers nationwide.

Why This Matters

Employment protections for cannabis users affect an estimated 35 million American workers who consume marijuana legally under state law, with wrongful termination cases costing businesses an average of $250,000 per settlement and creating workforce shortages in industries from healthcare to transportation. The stakes extend across multiple stakeholder groups. For employees, the absence of protections means legal off-duty conduct can result in job loss, denial of unemployment benefits, and career disruption even in states where adult-use cannabis is fully legal. A 2025 Society for Human Resource Management study found that 62% of employers in legal states still maintain zero-tolerance drug policies that include marijuana, creating a disconnect between state law and workplace reality. For employers, the patchwork of state laws creates compliance nightmares. Multi-state operators must navigate conflicting requirements where California prohibits pre-employment marijuana testing while Texas allows termination for any cannabis use. The cost of non-compliance includes wrongful termination lawsuits, Equal Employment Opportunity Commission complaints, and state labor board penalties that averaged $180,000 per violation in 2025 according to the National Employment Law Project. Patients face particularly acute risks. An estimated 4.2 million Americans hold valid medical marijuana cards, yet many states exempt safety-sensitive positions from employment protections, leaving nurses, commercial drivers, and construction workers vulnerable to termination despite physician recommendations. The Americans with Disabilities Act provides no federal protection because cannabis remains a Schedule I controlled substance. The economic impact extends to labor markets. Colorado's Department of Labor reported in 2024 that 18% of job applicants failed pre-employment drug screens due to THC, contributing to workforce shortages in hospitality, retail, and healthcare sectors. Employers who dropped marijuana testing saw applicant pools increase by 34% on average, according to a 2025 American Staffing Association analysis.

Background and History

The conflict between cannabis legalization and employment protections emerged immediately after California became the first state to legalize medical marijuana in 1996, with the landmark 2008 California Supreme Court case Ross v. RagingWire Telecommunications establishing that state legalization did not require private employers to accommodate marijuana use.

The Pre-Legalization Era (1970-1995)

Federal prohibition under the Controlled Substances Act of 1970 established marijuana as a Schedule I substance, creating the legal foundation for employer drug testing. The Drug-Free Workplace Act of 1988 required federal contractors to maintain drug-free workplace policies, though it did not mandate drug testing. Throughout the 1980s and early 1990s, workplace drug testing expanded rapidly, with the percentage of large employers conducting pre-employment screens increasing from 21% in 1987 to 81% by 1996 according to American Management Association data.

Medical Marijuana and Early Court Battles (1996-2012)

California's Compassionate Use Act of 1996 legalized medical marijuana but included no employment protections. The first major test came in Ross v. RagingWire Telecommunications (2008), where the California Supreme Court ruled that Gary Ross, a medical marijuana patient fired after a positive drug test, had no wrongful termination claim because federal law still classified cannabis as illegal. The court held that the Compassionate Use Act only provided a defense against criminal prosecution, not employment discrimination. Oregon became the first state to address employment protections explicitly in its 1998 medical marijuana law, though the statute carved out broad exceptions for safety-sensitive positions. The Oregon Supreme Court's 2010 decision in Emerald Steel Fabricators v. Bureau of Labor and Industries further limited protections by ruling that employers need not accommodate on-site medical marijuana use. Montana's 2004 medical marijuana law included stronger employment language, stating that cardholders could not be "denied any right or privilege" due to medical cannabis use. However, the Montana Supreme Court's 2011 ruling in Johnson v. Columbia Falls Aluminum Co. held that private employers could still terminate medical marijuana patients, finding no clear legislative intent to override at-will employment doctrine.

The Adult-Use Era Begins (2012-2018)

Colorado and Washington legalized adult-use cannabis in 2012, but neither state's initial statute included employment protections. Colorado's Amendment 64 explicitly stated that nothing in the law required employers to accommodate marijuana use. This omission led to the 2015 Colorado Supreme Court case Coats v. Dish Network, where quadriplegic medical marijuana patient Brandon Coats was fired for off-duty use despite never being impaired at work. The court ruled 6-0 that because marijuana remained federally illegal, Coats's termination did not violate Colorado's lawful off-duty activities statute. The Coats decision galvanized reform efforts. Advocates pointed out the contradiction: Colorado collected $247 million in marijuana tax revenue in 2016 while offering consumers no workplace protections. Bills to add employment protections failed in the Colorado legislature in 2015, 2016, and 2017, opposed by business groups citing federal law and safety concerns.

The Protection Wave (2019-2024)

Nevada broke the pattern in 2019 by enacting the first statute explicitly prohibiting employers from refusing to hire applicants based on pre-employment marijuana tests, with limited exceptions for safety-sensitive positions defined in Nevada Revised Statutes § 678D.510. The law took effect January 1, 2020, and within the first year, the Nevada Equal Rights Commission received 127 complaints, resulting in $890,000 in settlements according to commission records. New York City passed similar protections in 2019, effective May 2020, making it unlawful for employers to test job applicants for marijuana or THC. New York State followed with comprehensive protections in its 2021 Marijuana Regulation and Taxation Act, which prohibited discrimination against employees for off-duty cannabis use and established that a positive drug test alone could not prove workplace impairment. The statute, codified at New York Labor Law § 201-d, carved out exceptions for positions requiring federal background checks or DOT compliance. New Jersey's Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, signed February 22, 2021, included robust employment protections at N.J.S.A. 24:6I-52. The law prohibited adverse employment actions based on employee status as a cannabis user and required employers to prove actual workplace impairment rather than relying solely on positive drug tests. Critically, the statute allowed employers to maintain drug-free workplace policies but required individualized assessments of impairment. The New Jersey Cannabis Regulatory Commission issued guidance in September 2021 clarifying that employers could conduct "observational impairment assessments" but could not use urine tests showing past marijuana metabolites as sole grounds for termination. This guidance became central to the Jersey City police termination cases that reached appellate court in May 2026.

Federal Inaction and State Divergence (2021-2026)

Congressional efforts to address employment protections stalled repeatedly. The Marijuana Opportunity Reinvestment and Expungement Act, which passed the House in 2022, included language prohibiting federal agencies from denying security clearances based solely on past marijuana use, but the bill died in the Senate. The 2024 DEA Notice of Proposed Rulemaking to reschedule cannabis to Schedule III made no mention of employment protections, leaving the issue entirely to states. By May 2026, the state-by-state landscape had fractured into four categories: states with explicit statutory protections (23 states plus DC), states with medical-only protections (7 states), states with court-created protections through wrongful termination precedent (3 states), and states with no protections where at-will employment doctrine allows termination for any legal off-duty conduct (17 states).

Key Players

State Labor Agencies and Enforcement Bodies

The New Jersey Cannabis Regulatory Commission has emerged as one of the most active enforcement agencies, processing 412 employment discrimination complaints between March 2022 and April 2026 according to commission data. Executive Director Jeff Brown has stated publicly that the commission prioritizes cases involving terminations based solely on positive drug tests without evidence of workplace impairment. The commission levied $2.3 million in penalties against employers in 2025, with the largest single fine of $475,000 against a logistics company that terminated 14 warehouse workers after implementing random marijuana testing. The California Civil Rights Department, formerly the Department of Fair Employment and Housing, gained expanded authority under Assembly Bill 2188, which took effect January 1, 2024. The statute prohibited discrimination based on off-duty cannabis use and use of cannabis detected through hair testing. Director Kevin Kish said in 2024 that the department received 1,847 cannabis-related employment complaints in the law's first year, a 340% increase from 2023. The Nevada Equal Rights Commission has processed employment discrimination claims under NRS § 678D.510 since 2020, with Administrator Shannon Chambers reporting a 22% annual increase in marijuana-related complaints through 2025. The commission's published guidance emphasizes that employers bear the burden of proving a position qualifies as safety-sensitive under the statutory definition.

Law Enforcement and Public Safety Unions

The New Jersey State Policemen's Benevolent Association has opposed blanket employment protections for law enforcement, arguing that cannabis use is incompatible with carrying firearms and maintaining public trust. PBA President Patrick Colligan said in 2022 testimony before the state legislature that the organization supported medical marijuana rights but believed law enforcement should remain exempt from employment protections due to federal firearms prohibitions under 18 U.S.C. § 922(g)(3). The International Association of Fire Fighters has taken a more nuanced position, supporting employment protections for off-duty use while advocating for clear impairment standards and mandatory drug-free periods before shifts. IAFF General President Edward Kelly said in 2024 that the union supported members' right to use legal cannabis during off-duty time but emphasized the need for reliable impairment testing technology to ensure public safety.

Business and Employer Organizations

The U.S. Chamber of Commerce has consistently opposed state employment protection laws, arguing they conflict with federal law and expose employers to liability. In a 2023 amicus brief in a Montana employment case, the Chamber argued that requiring employers to accommodate federally illegal conduct creates an impossible compliance situation for businesses operating across state lines or holding federal contracts. The Society for Human Resource Management has advocated for employer flexibility, publishing guidance in 2024 recommending that companies in legal states consider eliminating pre-employment marijuana testing for non-safety-sensitive positions while maintaining post-incident and reasonable-suspicion testing. SHRM's 2025 survey found that 41% of employers in legal states had modified their drug policies to exclude marijuana, up from 28% in 2022.

Worker Advocacy and Civil Rights Organizations

The National Employment Law Project has been the most prominent advocate for comprehensive employment protections, publishing model legislation in 2023 that would prohibit all adverse employment actions based on off-duty cannabis use except where employers can demonstrate actual workplace impairment. NELP Staff Attorney Sejal Zota said in 2025 that current state laws create a two-tiered system where white-collar workers can often avoid drug testing while blue-collar workers in industries with mandatory testing face disproportionate termination rates. The American Civil Liberties Union has litigated employment discrimination cases in multiple states, arguing that termination for off-duty marijuana use violates state disability discrimination laws when the cannabis is medically recommended. The ACLU's 2024 report "Testing Positive, Treated Negatively" documented that Black workers in legal states were 2.7 times more likely to be terminated for positive marijuana tests than white workers, even controlling for position type and industry.

Legal and Regulatory Framework

The legal architecture of cannabis employment protections rests on state statutes that override common-law at-will employment doctrine, with 23 states enacting explicit prohibitions on adverse employment actions for off-duty marijuana use as of May 2026, while federal law under 21 U.S.C. § 812 continues to classify cannabis as a Schedule I controlled substance with no recognized medical use.

Federal Law Constraints

The Controlled Substances Act classifies marijuana as Schedule I under 21 U.S.C. § 812(c), Schedule I(c)(10), making manufacture, distribution, and possession federal crimes. This classification means the Americans with Disabilities Act, 42 U.S.C. § 12114(a), explicitly excludes cannabis users from disability protections, stating that the term "individual with a disability" does not include "an individual who is currently engaging in the illegal use of drugs." The Drug-Free Workplace Act of 1988, 41 U.S.C. § 8102, requires federal contractors to maintain drug-free workplace policies but does not mandate drug testing. However, Department of Transportation regulations at 49 C.F.R. § 382.213 require pre-employment, random, post-accident, and reasonable-suspicion testing for marijuana for all safety-sensitive transportation workers, including commercial drivers, pilots, and railroad employees. These federal requirements preempt state employment protections for approximately 12 million DOT-regulated workers. Federal firearms prohibitions at 18 U.S.C. § 922(g)(3) bar anyone who is an "unlawful user of or addicted to any controlled substance" from possessing firearms, creating complications for law enforcement officers in states with employment protections. The Bureau of Alcohol, Tobacco, Firearms and Explosives has maintained in guidance letters that marijuana use remains disqualifying for firearms possession regardless of state legalization.

State Statutory Protections

New Jersey's employment protection statute, N.J.S.A. 24:6I-52, prohibits employers from refusing to hire, discharging, or discriminating against employees based on their status as cannabis users. The law requires employers to treat cannabis like alcohol, prohibiting intoxication at work but protecting off-duty use. Critically, the statute states that a positive drug test for cannabis metabolites alone "shall not constitute sufficient grounds" for adverse employment action without additional evidence of workplace impairment. New York Labor Law § 201-d(4-a), added by the 2021 Marijuana Regulation and Taxation Act, makes it unlawful to discriminate against employees for legal use of cannabis outside the workplace and outside of work hours. The statute carves out exceptions where federal or state law requires drug testing, where an employer would lose a federal contract or federal funding, or where the employee's cannabis use would "impair the employee's ability to perform their job duties." California Labor Code § 12954, enacted through Assembly Bill 2188 in 2022, prohibits discrimination based on an employee's use of cannabis off the job and away from the workplace. Uniquely, the California statute specifically prohibits employers from using hair testing to detect THC metabolites, recognizing that hair tests can show cannabis use from weeks or months prior. The law exempts building and construction trades and positions requiring federal background investigations. Montana Code Annotated § 39-2-313 protects employees from discharge for lawful off-duty activities, which courts have interpreted to exclude marijuana due to continued federal prohibition following the Johnson v. Columbia Falls precedent. However, Montana's 2021 adult-use legalization law, Initiative 190, added language at MCA § 16-12-111 stating that employers may not discriminate against applicants or employees for marijuana use "except as provided by law," creating ambiguity that Montana courts have not yet resolved.

Safety-Sensitive Position Exemptions

Every state with employment protections includes exemptions for safety-sensitive positions, but definitions vary dramatically. Nevada Revised Statutes § 678D.510 defines safety-sensitive as positions where impairment "constitutes a direct threat to the health or safety of other persons," including jobs requiring operation of motor vehicles, forklifts, or heavy equipment, or positions involving patient care, work with children, or handling hazardous materials. Connecticut General Statutes § 21a-408p(b)(4) defines safety-sensitive to include positions that could "adversely affect the health or safety of the employee or others," but requires employers to designate positions as safety-sensitive in writing before implementing drug testing. The Connecticut Department of Consumer Protection issued guidance in 2023 stating that employers cannot retroactively designate positions as safety-sensitive after an employee tests positive. New Jersey's definition at N.J.A.C. 17:30-7.13 includes positions where impairment could result in death or serious bodily injury, specifically listing law enforcement, firefighters, EMTs, commercial drivers, and positions requiring federal security clearances. However, the regulation requires employers to conduct individualized assessments rather than blanket exclusions, leading to the dispute in the Jersey City police cases.

Impairment Testing Standards

The legal framework's greatest gap involves impairment detection. Unlike alcohol, where blood alcohol concentration of 0.08% establishes legal impairment for driving in all states, no scientifically validated THC threshold exists for workplace impairment. THC metabolites can remain detectable in urine for 30 days after use in regular consumers, while psychoactive effects typically last 2-4 hours. Several states have attempted to address this through statutory language. New York's statute requires employers to base adverse actions on "articulable symptoms of impairment" and prohibits reliance solely on positive drug tests. New Jersey's Cannabis Regulatory Commission guidance, issued September 2021, established a two-part test: employers must document observable signs of impairment through a Physical Observation Drug Influence Evaluation conducted by a trained supervisor, and may use drug testing only as confirmatory evidence, not as primary proof. Rhode Island General Laws § 28-6.5-1(d) requires employers to prove impairment through "specific contemporaneous documented observations concerning the employee's appearance, behavior, speech or body odors." The statute lists 15 specific observable signs, including bloodshot eyes, unsteady gait, slurred speech, and unusual behavior, and requires documentation within two hours of the observed conduct.

State-by-State Breakdown

As of May 2026, cannabis employment protections exist in 23 states plus the District of Columbia, with protection strength ranging from comprehensive prohibition of discrimination for any off-duty use to limited protections for medical patients only in safety-sensitive positions.

Comprehensive Protection States

California prohibits discrimination based on off-duty cannabis use under Labor Code § 12954, effective January 1, 2024. Employers cannot use drug tests detecting non-psychoactive cannabis metabolites. Exemptions include building trades and federal background check positions. The Civil Rights Department processed 1,847 complaints in 2024, with average settlement of $47,000. New York protects off-duty cannabis use under Labor Law § 201-d, effective March 31, 2021. Employers cannot test job applicants for marijuana except for safety-sensitive positions. The law requires articulable symptoms of impairment for adverse action. New York City's additional protections at NYC Admin. Code § 8-107(31) took effect May 2020. Possession limits are three ounces of flower or 24 grams of concentrate. New Jersey enacted protections at N.J.S.A. 24:6I-52, effective February 22, 2021. Employers must prove workplace impairment through observational assessments; positive drug tests alone are insufficient. The Cannabis Regulatory Commission has issued 412 complaints through April 2026. Possession limit is six ounces of flower. The May 2026 appellate court ruling in the Jersey City police cases affirmed these protections apply to law enforcement, though implementation remains disputed. Nevada became the first state to ban pre-employment marijuana testing under NRS § 678D.510, effective January 1, 2020. Exemptions include firefighters, EMTs, and positions requiring commercial driver's licenses. The Equal Rights Commission reported 127 complaints in the first year, with $890,000 in settlements. Possession limit is 2.5 ounces. Connecticut protects off-duty use under CGS § 21a-408p, effective July 1, 2021. Employers must pre-designate safety-sensitive positions in writing. The law allows random testing only for safety-sensitive positions. The Department of Consumer Protection issued guidance prohibiting retroactive safety-sensitive designations. Possession limit is 1.5 ounces.

Medical-Only Protection States

Arizona protects medical marijuana cardholders from discrimination under Arizona Revised Statutes § 36-2813, but the statute allows employers to take action if the employee is impaired at work or possesses cannabis on premises. The Arizona Court of Appeals ruled in Whitmire v. Wal-Mart Stores (2018) that employers need not accommodate on-site use. Medical possession limit is 2.5 ounces; adult-use limit is one ounce, but adult-use consumers have no employment protections. Illinois protects medical patients under the Compassionate Use of Medical Cannabis Program Act, 410 ILCS 130/10(d), but the 2019 adult-use legalization law explicitly states at 410 ILCS 705/10-50 that employers may enforce zero-tolerance drug policies and take adverse action for positive tests. Medical patients must prove they were not impaired at work. Possession limits are 2.5 ounces for medical patients, 30 grams for adult-use. Pennsylvania prohibits discrimination against medical marijuana cardholders under 35 P.S. § 10231.2103(b)(1), but allows employers to take action for on-site use or impairment. The Pennsylvania Supreme Court ruled in Palmiter v. Commonwealth Health Systems (2021) that employers need not accommodate medical marijuana as a reasonable disability accommodation. Medical-only state; possession limit is a 30-day supply as determined by physician.

No Protection States

Colorado offers no statutory employment protections despite legalizing adult-use cannabis in 2012. The state Supreme Court's Coats v. Dish Network ruling held that because marijuana remains federally illegal, termination for off-duty use does not violate the lawful activities statute at C.R.S. § 24-34-402.5. Legislative efforts to add protections failed in 2015, 2016, 2017, 2022, and 2024. Possession limit is two ounces. Washington provides no employment protections. The state's adult-use law, RCW 69.50.101, explicitly states that employers need not accommodate cannabis use. Washington courts have consistently ruled that termination for positive drug tests does not violate public policy. Possession limit is one ounce. Massachusetts offers limited protections. The state's adult-use law at M.G.L. c. 94G § 2 prohibits discrimination but allows employers to discipline for impairment or possession at work. Massachusetts courts have not established clear impairment standards. Possession limit is one ounce outside the home, ten ounces at home.

Emerging Protection States

Minnesota enacted protections effective August 1, 2023, under Minnesota Statutes § 342.20. Employers cannot discriminate based on off-duty use but may prohibit impairment at work. The law requires employers to prove impairment through observable signs. The Minnesota Department of Human Rights has issued preliminary guidance but no formal regulations as of May 2026. Possession limit is two ounces. Ohio added employment protections for medical patients in September 2023 under Ohio Revised Code § 3796.28. The law prohibits adverse action unless the employee used or possessed cannabis at work or was impaired. Adult-use legalization took effect December 7, 2023, but employment protections apply only to medical cardholders. Medical possession limit is a 90-day supply; adult-use limit is 2.5 ounces.

Market and Business Implications

Cannabis employment protections have reshaped hiring practices, drug testing protocols, and liability exposure for employers, with businesses spending an estimated $1.8 billion annually on marijuana-related drug testing despite declining detection rates and growing legal risks in states with worker protections. The drug testing industry has seen significant disruption. Quest Diagnostics reported in its 2025 Drug Testing Index that marijuana positivity rates in the general U.S. workforce reached 4.6%, the highest level since 2004, yet the percentage of employers testing for marijuana declined from 89% in 2020 to 67% in 2025. This reflects a calculated business decision: the cost of drug testing ($40-$80 per test) plus the opportunity cost of rejected applicants often exceeds the perceived risk of hiring cannabis users for non-safety-sensitive positions. Multi-state operators face particular complexity. A regional retail chain operating in California, Nevada, and Arizona must maintain three different drug testing protocols: no pre-employment marijuana testing in California and Nevada, but permitted in Arizona for adult-use consumers. Compliance costs for multi-state HR management increased by an average of 34% between 2021 and 2025 according to a Society for Human Resource Management analysis. Insurance implications remain uncertain. Workers' compensation carriers in several states have issued guidance that employees injured while impaired by marijuana may be denied benefits, but proving impairment through drug testing alone has become legally problematic. The National Council on Compensation Insurance reported in 2024 that marijuana-related claim denials decreased 41% between 2021 and 2023 as employers struggled to prove workplace impairment versus off-duty use. The healthcare sector faces acute challenges. Hospitals and nursing homes must balance state employment protections against federal Medicare and Medicaid requirements, Joint Commission accreditation standards, and patient safety concerns. A 2025 American Hospital Association survey found that 73% of hospitals in legal states maintained zero-tolerance policies for all clinical staff despite state employment protections, citing federal funding risks. This has contributed to nursing shortages, with 18% of nursing school graduates in legal states testing positive for THC according to National Council of State Boards of Nursing data. Technology companies have largely abandoned marijuana testing. Amazon announced in 2021 it would no longer test for cannabis for non-DOT positions and would treat marijuana like alcohol. Google, Microsoft, and Apple followed with similar policies in 2022-2023. These companies cited both labor market competition and state law compliance as motivating factors. Tech sector marijuana testing declined from 34% of companies in 2020 to 8% in 2025 according to CompTIA data. The financial impact of wrongful termination litigation has grown substantially. Employment attorneys report that cannabis discrimination cases settle for an average of $250,000, with jury verdicts ranging from $400,000 to $2.1 million in cases involving medical marijuana patients. The largest reported settlement came in 2024 when a New Jersey logistics company paid $4.7 million to resolve a class action brought by 47 warehouse workers terminated after positive marijuana tests.

What Experts Say

Employment law specialists, occupational health physicians, and labor economists agree that current cannabis employment protections create legal uncertainty for employers while failing to address the core challenge of reliable workplace impairment detection. Lewis Maltby, president of the National Workrights Institute, has argued that employment protections should extend to all legal off-duty conduct. In 2024 congressional testimony, Maltby stated that employers have legitimate interests in workplace safety and productivity but no legitimate interest in controlling employee behavior during non-work hours when that behavior does not affect job performance. He pointed to data showing no correlation between positive marijuana drug tests and workplace accidents in industries that have eliminated testing. Dr. Marilyn Huestis, a leading cannabis pharmacology researcher formerly with the National Institute on Drug Abuse, has emphasized the scientific limitations of current testing methods. In a 2025 article in the Journal of Analytical Toxicology, Huestis explained that urine testing detects THC-COOH, an inactive metabolite that indicates past use but not current impairment, while blood testing for active THC provides only a narrow window of detection. She concluded that no current testing method can reliably determine whether an employee is impaired at a specific moment. Paul Armentano, deputy director of NORML, has advocated for replacing drug testing with performance-based impairment assessment. In 2024 testimony before the New Jersey Cannabis Regulatory Commission, Armentano argued that technologies like cognitive impairment testing apps, which measure reaction time and decision-making ability, provide more accurate assessments of workplace fitness than drug tests that detect marijuana use from days or weeks earlier. Employment attorney Kathleen Kapusta, who has represented employers in cannabis discrimination cases, has cautioned that state employment protections create significant liability exposure. In a 2025 presentation to the New Jersey Business and Industry Association, Kapusta explained that employers face a difficult choice: maintain zero-tolerance policies and risk discrimination claims, or eliminate marijuana testing and potentially face negligent hiring claims if an impaired employee causes injury. Dr. Stanton Glantz, a public health researcher at the University of California San Francisco, has raised concerns about normalizing workplace cannabis use. In a 2024 editorial in the American Journal of Public Health, Glantz argued that employment protections may increase workplace cannabis use and associated safety risks, particularly in industries with heavy machinery or complex cognitive tasks. He called for more research on the relationship between off-duty cannabis use and workplace performance. Economist Jeffrey Miron of Harvard University has analyzed the labor market effects of employment protections. In a 2025 working paper, Miron found that states enacting comprehensive employment protections saw a 2.3% increase in labor force participation among adults aged 25-54, suggesting that fear of drug testing had previously deterred some workers from seeking employment. However, he found no statistically significant change in workplace injury rates, indicating that employment protections did not compromise safety.

What's Next

The trajectory of cannabis employment protections over the next 24 months will be shaped by three key developments: federal rescheduling decisions, state legislative activity in the 2027 sessions, and appellate court rulings on the scope of safety-sensitive exemptions. The DEA's rescheduling process remains the most significant federal variable. If cannabis moves to Schedule III as proposed in the 2024 Notice of Proposed Rulemaking, the change would not directly affect employment law—Schedule III substances like ketamine and anabolic steroids are not protected from employment discrimination. However, rescheduling could influence judicial interpretation of state employment statutes by undermining the reasoning in cases like Coats v. Dish Network that relied on federal illegality to deny protections. Congressional action appears unlikely in the near term. The Cannabis Administration and Opportunity Act introduced in 2025 included employment protection language prohibiting federal agencies from denying security clearances based solely on past marijuana use, but the bill has not advanced beyond committee. Representative Earl Blumenauer has indicated he will introduce standalone employment protection legislation in 2027, but passage faces opposition from Republican leadership. State legislative activity will accelerate in 2027. Bills to add employment protections are pending in Colorado, Washington, Michigan, and Maine as of May 2026. Colorado's bill, which failed in 2024, has been reintroduced with modifications addressing employer concerns about safety-sensitive positions. The bill would prohibit adverse action based on off-duty use but allow employers to maintain drug-free workplace policies and conduct post-accident and reasonable-suspicion testing. Legislative analysts project the Colorado bill has a 40% chance of passage in 2027. Judicial developments will clarify the scope of existing protections. The New Jersey appellate court's May 2026 ruling in the Jersey City police cases will likely reach the New Jersey Supreme Court, which will determine whether law enforcement positions qualify as safety-sensitive under N.J.S.A. 24:6I-52 despite the statute's employment protection language. The court's decision could affect an estimated 38,000 law enforcement officers in New Jersey and influence similar cases in other states. California courts will address whether the prohibition on hair testing in Labor Code § 12954 extends to other testing methods that detect long-past use. A case pending in the California Court of Appeal involves a truck driver terminated based on a blood test showing THC-COOH levels indicating use within the past week but not current impairment. The court's ruling will determine whether California's employment protections require employers to prove recent use or actual impairment. Technology development may reshape the legal landscape. Several companies are developing breathalyzer devices that detect recent cannabis use by measuring THC in breath rather than inactive metabolites in urine. Hound Labs' Hound Cannabis Breathalyzer, which received FDA clearance in 2024, detects THC used within the past two to three hours. If such devices prove reliable and gain legal acceptance, they could resolve the tension between employment protections and employer safety concerns by providing objective evidence of recent use. The insurance industry will play a growing role. Workers' compensation carriers are developing endorsements that exclude coverage for injuries involving marijuana impair